Navigation auf uzh.ch
The inflammatory response upon acute ST-segment elevation myocardial infarction (STEMI) affects myocardial infarct (MI) size and eventually left ventricular remodeling. The mammalian target of rapamycin (mTOR) is centrally involved in this process and its inhibition has exerted beneficial effects on MI size in preclinical models of acute MI. In this original article, B. Stähli and R. Klingenberg et al. evaluated the effects of targeting inflammation by mTOR inhibition in patients with STEMI undergoing percutaneous coronary intervention (PCI). The authors conclude, that early mTOR inhibition with everolimus did not reduce MI size or MVO at 30 days in STEMI patients undergoing PCI. Full study results now available at jacc.org.